Dx&Vx said on Monday it signed a $4 million export supply contract with Ofmeight, a Vietnamese company specializing in the direct distribution of health and beauty (H&B) products. This agreement marks a shift from previous export focuses in China, aiming to broaden their reach across Southeast Asia, Japan, the U.S., and other international markets, the company said.
Under the terms of the agreement, Dx&Vx will supply its Mate series, which utilizes the European-patented SynterAct Technology developed by COREE Italy AAT Research Institute, alongside a line of H&B probiotics tailored for women in their 20s and 30s.
Ofmeight views this partnership as “pivotal” for enhancing its position in Vietnam’s women’s healthcare market. Đỗ Thi Hồng Đào, CEO of Ofmeight, expressed confidence in the collaboration’s potential to drive mutual growth, particularly in Vietnam’s expanding baby formula and healthcare market.
"Ofmom products, developed and produced directly by companies involved in vaccine and pharmaceutical research and development, are trusted for their quality compared to other products,” he said.
Ofmeight also plans to open branded malls for Ofmom and Dx&Vx on Vietnam's most-used online shopping platforms, including TikTok, Shopee, and Lazada within the next quarter.
Additionally, it will actively engage in brand marketing activities across Korea, Italy, and Vietnam, centered around social media to cater to evolving consumer habits influenced by digital culture.
"This agreement serves as a gateway to the entire Southeast Asian market," said Park Seong-rock, Director of Dx&Vx’s online business division, highlighting their plans to establish Ofmom and Dx&Vx as leading global healthcare brands, with a target of 30 percent of total revenue from international markets. “Discussions are underway for additional export supply agreements in the U.S., Japan, and other key markets.”
Related articles
- AriBio sets up drug marketing network with Vietnamese state enterprise
- S.Thepharm gets nod for hyaluronic acid fillers in Vietnam
- Samsung Biologics secures $223 million contract with Baxter Healthcare
- Hanmi Pharm's Rolontis moves quickly to expand overseas markets
- Korea's regulatory excellence propels vaccine makers to international heights
- BlueMTec enters Vietnam's hospital drug distribution market
- Dx&Vx, Yungjin Pharmaceutical to co-develop AI-powered anticancer drugs
- Dx&Vx hires a peptide expert as managing director
- Dx&Vx partners with Stanford to develop Covid-19 vaccine
